Skip to Main Content

Paper Details

Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes.
Br J Ophthalmol
14
2023
Author NameAffiliation
Neil M BresslerJohns Hopkins Medicine Wilmer Eye Institute
  • 1 - 1

Datasets

Release 1.2